Scott Cramer
Concepts (432)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 39 | 2025 | 981 | 3.940 |
Why?
| | MAP Kinase Kinase Kinases | 8 | 2021 | 70 | 2.250 |
Why?
| | Prostate | 11 | 2014 | 159 | 1.800 |
Why?
| | Receptors, Androgen | 8 | 2021 | 149 | 1.130 |
Why?
| | DNA Helicases | 4 | 2021 | 136 | 1.110 |
Why?
| | Prostate-Specific Antigen | 9 | 2013 | 161 | 0.940 |
Why?
| | Hyperoxaluria, Primary | 5 | 2009 | 14 | 0.880 |
Why?
| | Epithelial Cells | 10 | 2016 | 1134 | 0.840 |
Why?
| | Calcitriol | 6 | 2011 | 58 | 0.830 |
Why?
| | Vitamin D | 4 | 2013 | 404 | 0.820 |
Why?
| | DNA-Binding Proteins | 5 | 2021 | 1482 | 0.770 |
Why?
| | Alcohol Oxidoreductases | 7 | 2011 | 61 | 0.760 |
Why?
| | Interleukin-1alpha | 2 | 2013 | 57 | 0.720 |
Why?
| | Stromal Cells | 2 | 2014 | 121 | 0.610 |
Why?
| | RNA Interference | 2 | 2021 | 475 | 0.600 |
Why?
| | Homologous Recombination | 1 | 2019 | 37 | 0.590 |
Why?
| | Androgens | 4 | 2021 | 181 | 0.550 |
Why?
| | Stem Cells | 3 | 2011 | 630 | 0.490 |
Why?
| | DNA Damage | 1 | 2019 | 437 | 0.480 |
Why?
| | Receptors, Calcitriol | 5 | 2015 | 56 | 0.480 |
Why?
| | Cell Line, Tumor | 17 | 2021 | 3551 | 0.470 |
Why?
| | Cell Division | 9 | 2011 | 757 | 0.470 |
Why?
| | Tumor Suppressor Proteins | 2 | 2012 | 322 | 0.450 |
Why?
| | Epoxy Compounds | 2 | 2015 | 31 | 0.450 |
Why?
| | Carnitine O-Palmitoyltransferase | 2 | 2015 | 49 | 0.440 |
Why?
| | Autophagy | 5 | 2020 | 291 | 0.440 |
Why?
| | Genomic Instability | 1 | 2015 | 68 | 0.440 |
Why?
| | Anticarcinogenic Agents | 2 | 2014 | 63 | 0.420 |
Why?
| | Lactones | 1 | 2014 | 59 | 0.410 |
Why?
| | Breast | 2 | 2014 | 156 | 0.400 |
Why?
| | Genistein | 2 | 2004 | 13 | 0.390 |
Why?
| | Signal Transduction | 7 | 2022 | 5223 | 0.390 |
Why?
| | Cell Proliferation | 9 | 2021 | 2514 | 0.380 |
Why?
| | Enzyme Inhibitors | 3 | 2014 | 821 | 0.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1969 | 0.370 |
Why?
| | Nuclear Proteins | 2 | 2015 | 740 | 0.360 |
Why?
| | Repressor Proteins | 1 | 2015 | 429 | 0.360 |
Why?
| | Cell Cycle | 4 | 2021 | 598 | 0.360 |
Why?
| | Animals | 35 | 2025 | 38097 | 0.360 |
Why?
| | Cells, Cultured | 13 | 2015 | 4151 | 0.350 |
Why?
| | Mice | 25 | 2022 | 18355 | 0.350 |
Why?
| | Male | 52 | 2025 | 73003 | 0.340 |
Why?
| | Intermediate Filament Proteins | 1 | 2011 | 57 | 0.330 |
Why?
| | Adult Stem Cells | 1 | 2011 | 40 | 0.330 |
Why?
| | Chromones | 1 | 2010 | 43 | 0.330 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2013 | 2181 | 0.320 |
Why?
| | Neoplastic Stem Cells | 2 | 2011 | 409 | 0.320 |
Why?
| | Mice, Knockout | 8 | 2015 | 3130 | 0.310 |
Why?
| | Necrosis | 4 | 2020 | 244 | 0.310 |
Why?
| | Morpholines | 1 | 2010 | 130 | 0.310 |
Why?
| | Nerve Tissue Proteins | 2 | 2011 | 592 | 0.300 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2011 | 440 | 0.300 |
Why?
| | Gene Deletion | 3 | 2011 | 392 | 0.280 |
Why?
| | Pregnancy, Animal | 3 | 1992 | 51 | 0.270 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 508 | 0.270 |
Why?
| | Cell Differentiation | 4 | 2014 | 2050 | 0.260 |
Why?
| | Humans | 60 | 2025 | 145763 | 0.260 |
Why?
| | Mutation, Missense | 3 | 2009 | 335 | 0.260 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2011 | 293 | 0.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2021 | 1450 | 0.240 |
Why?
| | Hyperoxaluria | 2 | 2011 | 3 | 0.240 |
Why?
| | Clinical Enzyme Tests | 1 | 2006 | 9 | 0.240 |
Why?
| | Promoter Regions, Genetic | 4 | 2009 | 1247 | 0.240 |
Why?
| | Prostatic Hyperplasia | 2 | 2004 | 40 | 0.240 |
Why?
| | Spectrophotometry | 1 | 2006 | 58 | 0.240 |
Why?
| | Gene Expression Regulation | 6 | 2011 | 2601 | 0.240 |
Why?
| | Calcifediol | 3 | 2015 | 31 | 0.230 |
Why?
| | PTEN Phosphohydrolase | 5 | 2019 | 165 | 0.230 |
Why?
| | Cell Lineage | 1 | 2007 | 378 | 0.230 |
Why?
| | Genotype | 7 | 2008 | 1857 | 0.220 |
Why?
| | Systems Biology | 1 | 2025 | 68 | 0.210 |
Why?
| | Pancreatic Neoplasms | 2 | 2011 | 928 | 0.210 |
Why?
| | Biomarkers, Tumor | 4 | 2019 | 1329 | 0.210 |
Why?
| | Cyclins | 1 | 2004 | 79 | 0.200 |
Why?
| | Allelic Imbalance | 1 | 2003 | 9 | 0.200 |
Why?
| | Endocrinology | 1 | 2004 | 77 | 0.200 |
Why?
| | Polymorphism, Genetic | 2 | 2003 | 615 | 0.190 |
Why?
| | Proteins | 4 | 1997 | 1023 | 0.190 |
Why?
| | Cell Cycle Proteins | 3 | 2010 | 630 | 0.190 |
Why?
| | Leukocytes, Mononuclear | 1 | 2006 | 574 | 0.190 |
Why?
| | Fibroblasts | 2 | 2014 | 1027 | 0.190 |
Why?
| | Apoptosis | 6 | 2016 | 2443 | 0.190 |
Why?
| | Tumor Cells, Cultured | 8 | 2015 | 887 | 0.190 |
Why?
| | Specimen Handling | 1 | 2004 | 183 | 0.190 |
Why?
| | Receptors, Somatotropin | 2 | 1992 | 10 | 0.190 |
Why?
| | Linkage Disequilibrium | 1 | 2003 | 255 | 0.190 |
Why?
| | Cell Communication | 1 | 2004 | 327 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2004 | 2219 | 0.170 |
Why?
| | Parathyroid Hormone | 3 | 1997 | 114 | 0.170 |
Why?
| | Drug Synergism | 3 | 2010 | 354 | 0.170 |
Why?
| | Phenylthiohydantoin | 1 | 2021 | 44 | 0.170 |
Why?
| | Logistic Models | 2 | 2021 | 2139 | 0.160 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2015 | 19 | 0.160 |
Why?
| | Prostatectomy | 2 | 2013 | 94 | 0.160 |
Why?
| | Mutation | 3 | 2007 | 4090 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1150 | 0.160 |
Why?
| | Cell Line | 7 | 2012 | 2823 | 0.150 |
Why?
| | Pyroptosis | 1 | 2020 | 5 | 0.150 |
Why?
| | Benzamides | 1 | 2021 | 226 | 0.150 |
Why?
| | Carrier Proteins | 3 | 1992 | 729 | 0.150 |
Why?
| | Nitriles | 1 | 2021 | 211 | 0.150 |
Why?
| | Colony-Forming Units Assay | 2 | 2011 | 95 | 0.150 |
Why?
| | Immunoblotting | 3 | 2010 | 295 | 0.150 |
Why?
| | Neoplasms | 2 | 2014 | 2913 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 365 | 0.150 |
Why?
| | Molecular Sequence Data | 6 | 2009 | 2883 | 0.140 |
Why?
| | Polymerase Chain Reaction | 6 | 2009 | 1043 | 0.140 |
Why?
| | Point Mutation | 1 | 1999 | 241 | 0.140 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2018 | 43 | 0.140 |
Why?
| | Osteoblasts | 2 | 1996 | 145 | 0.140 |
Why?
| | Cellular Senescence | 2 | 2011 | 226 | 0.140 |
Why?
| | Mice, Nude | 3 | 2015 | 680 | 0.140 |
Why?
| | Genetic Markers | 2 | 2013 | 338 | 0.130 |
Why?
| | NAD | 1 | 2018 | 79 | 0.130 |
Why?
| | Meningeal Neoplasms | 1 | 2019 | 95 | 0.130 |
Why?
| | RNA, Small Interfering | 3 | 2011 | 638 | 0.130 |
Why?
| | Gene Expression | 5 | 2018 | 1478 | 0.130 |
Why?
| | Transfection | 5 | 2018 | 927 | 0.130 |
Why?
| | Regeneration | 2 | 2011 | 198 | 0.130 |
Why?
| | Flow Cytometry | 4 | 2011 | 1165 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 883 | 0.130 |
Why?
| | Base Sequence | 6 | 2009 | 2171 | 0.130 |
Why?
| | Membrane Glycoproteins | 2 | 2018 | 499 | 0.120 |
Why?
| | Neoplasm Grading | 2 | 2015 | 311 | 0.120 |
Why?
| | Cadherins | 2 | 2015 | 200 | 0.120 |
Why?
| | Cyclic AMP | 1 | 1996 | 208 | 0.110 |
Why?
| | Oxalates | 3 | 2011 | 11 | 0.110 |
Why?
| | Transforming Growth Factor beta2 | 2 | 2014 | 33 | 0.110 |
Why?
| | Recombination, Genetic | 2 | 2007 | 205 | 0.110 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 8 | 0.110 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 13 | 0.110 |
Why?
| | Vesiculovirus | 1 | 2015 | 17 | 0.110 |
Why?
| | Down-Regulation | 2 | 2014 | 618 | 0.110 |
Why?
| | Endotoxins | 1 | 2015 | 217 | 0.110 |
Why?
| | Receptors, Eicosanoid | 2 | 2005 | 2 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 161 | 0.100 |
Why?
| | Metabolism | 1 | 2014 | 44 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2005 | 106 | 0.100 |
Why?
| | Adenocarcinoma | 2 | 2019 | 926 | 0.100 |
Why?
| | Lipid Metabolism | 2 | 2015 | 529 | 0.100 |
Why?
| | Oxidation-Reduction | 2 | 2015 | 1068 | 0.100 |
Why?
| | Liver | 3 | 2004 | 1899 | 0.100 |
Why?
| | Random Allocation | 1 | 2014 | 365 | 0.100 |
Why?
| | Proto-Oncogenes | 1 | 2013 | 28 | 0.100 |
Why?
| | Luciferases | 2 | 2003 | 154 | 0.090 |
Why?
| | Litter Size | 1 | 1992 | 18 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 337 | 0.090 |
Why?
| | Silymarin | 1 | 2014 | 147 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2011 | 751 | 0.090 |
Why?
| | DNA Copy Number Variations | 1 | 2013 | 188 | 0.090 |
Why?
| | Hydroxyproline | 1 | 2011 | 18 | 0.090 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2011 | 24 | 0.090 |
Why?
| | Electrophoresis | 1 | 2011 | 31 | 0.090 |
Why?
| | Genes, Retinoblastoma | 1 | 2011 | 9 | 0.090 |
Why?
| | Genes, p16 | 1 | 2011 | 13 | 0.090 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2011 | 96 | 0.080 |
Why?
| | Nestin | 1 | 2011 | 19 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 936 | 0.080 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2011 | 79 | 0.080 |
Why?
| | Ribonucleosides | 1 | 2010 | 7 | 0.080 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2011 | 108 | 0.080 |
Why?
| | Oxadiazoles | 1 | 2010 | 37 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-pim-1 | 1 | 2010 | 2 | 0.080 |
Why?
| | Cell Separation | 1 | 2011 | 306 | 0.080 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2010 | 19 | 0.080 |
Why?
| | Organ Specificity | 1 | 2011 | 309 | 0.080 |
Why?
| | Amino Acid Sequence | 3 | 2000 | 2131 | 0.080 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2011 | 143 | 0.080 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2010 | 19 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2015 | 910 | 0.080 |
Why?
| | Disease Progression | 2 | 2015 | 2865 | 0.080 |
Why?
| | Hydroxypyruvate Reductase | 2 | 2000 | 2 | 0.080 |
Why?
| | Glucose | 1 | 2015 | 1048 | 0.080 |
Why?
| | Expressed Sequence Tags | 2 | 2000 | 43 | 0.080 |
Why?
| | Parathyroid Hormone-Related Protein | 4 | 1997 | 25 | 0.080 |
Why?
| | YY1 Transcription Factor | 1 | 2009 | 24 | 0.070 |
Why?
| | DNA, Complementary | 2 | 2000 | 273 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1331 | 0.070 |
Why?
| | Prostatic Secretory Proteins | 1 | 2009 | 4 | 0.070 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 3 | 2016 | 54 | 0.070 |
Why?
| | Physical Chromosome Mapping | 1 | 2009 | 21 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2015 | 877 | 0.070 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2009 | 20 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2000 | 387 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 5 | 2009 | 2399 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 383 | 0.070 |
Why?
| | Ataxins | 1 | 2007 | 4 | 0.070 |
Why?
| | Ataxin-1 | 1 | 2007 | 4 | 0.070 |
Why?
| | Hypoglycemic Agents | 2 | 2015 | 1399 | 0.070 |
Why?
| | Integrin alpha6 | 1 | 2007 | 9 | 0.070 |
Why?
| | Growth Hormone | 3 | 1992 | 91 | 0.070 |
Why?
| | Risk Factors | 2 | 2021 | 10917 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 298 | 0.070 |
Why?
| | RNA-Binding Proteins | 3 | 2022 | 447 | 0.070 |
Why?
| | Rats | 4 | 2015 | 5585 | 0.070 |
Why?
| | Gene Frequency | 1 | 2009 | 489 | 0.070 |
Why?
| | Response Elements | 2 | 2009 | 86 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 428 | 0.060 |
Why?
| | Alleles | 2 | 2008 | 896 | 0.060 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2007 | 47 | 0.060 |
Why?
| | Cell Movement | 1 | 2012 | 961 | 0.060 |
Why?
| | Culture Media, Serum-Free | 2 | 2005 | 42 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 528 | 0.060 |
Why?
| | Clone Cells | 1 | 2007 | 263 | 0.060 |
Why?
| | Chromosome Deletion | 1 | 2007 | 126 | 0.060 |
Why?
| | Japan | 1 | 2007 | 149 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 2 | 2005 | 35 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 979 | 0.060 |
Why?
| | Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2016 | 14 | 0.060 |
Why?
| | Carbohydrate Dehydrogenases | 1 | 2006 | 8 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2007 | 376 | 0.060 |
Why?
| | Blotting, Western | 2 | 2006 | 1184 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2028 | 0.060 |
Why?
| | Middle Aged | 9 | 2013 | 36302 | 0.060 |
Why?
| | Genetic Vectors | 1 | 2007 | 335 | 0.060 |
Why?
| | RNA, Messenger | 5 | 2011 | 2805 | 0.060 |
Why?
| | DNA, Neoplasm | 2 | 2003 | 160 | 0.060 |
Why?
| | Prostatic Diseases | 1 | 2005 | 4 | 0.060 |
Why?
| | Parainfluenza Virus 5 | 1 | 2005 | 1 | 0.060 |
Why?
| | Viral Structural Proteins | 1 | 2005 | 12 | 0.060 |
Why?
| | Arachidonic Acids | 1 | 2005 | 42 | 0.060 |
Why?
| | Vesicular stomatitis Indiana virus | 1 | 2004 | 13 | 0.050 |
Why?
| | Viral Matrix Proteins | 1 | 2004 | 28 | 0.050 |
Why?
| | Tolonium Chloride | 1 | 2004 | 4 | 0.050 |
Why?
| | ADP Ribose Transferases | 1 | 2004 | 9 | 0.050 |
Why?
| | DNA Mutational Analysis | 2 | 2009 | 410 | 0.050 |
Why?
| | Glycolates | 1 | 2004 | 6 | 0.050 |
Why?
| | Glyoxylates | 1 | 2004 | 8 | 0.050 |
Why?
| | Reference Values | 1 | 2006 | 798 | 0.050 |
Why?
| | Coloring Agents | 1 | 2004 | 89 | 0.050 |
Why?
| | Calcium Channel Agonists | 1 | 2004 | 12 | 0.050 |
Why?
| | Steroid Hydroxylases | 1 | 2004 | 20 | 0.050 |
Why?
| | Interferon Type I | 1 | 2005 | 147 | 0.050 |
Why?
| | MicroRNAs | 1 | 2010 | 686 | 0.050 |
Why?
| | Ergocalciferols | 1 | 2003 | 14 | 0.050 |
Why?
| | Lung | 2 | 2015 | 4116 | 0.050 |
Why?
| | Microscopy, Fluorescence | 1 | 2005 | 408 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2003 | 1300 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2003 | 778 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2013 | 2123 | 0.050 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2003 | 43 | 0.050 |
Why?
| | beta-Galactosidase | 1 | 2003 | 76 | 0.050 |
Why?
| | Palpation | 1 | 2003 | 15 | 0.050 |
Why?
| | Trinucleotide Repeats | 1 | 2003 | 31 | 0.050 |
Why?
| | Adult | 6 | 2013 | 40872 | 0.050 |
Why?
| | Gene Amplification | 1 | 2003 | 118 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2004 | 162 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1454 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2005 | 337 | 0.050 |
Why?
| | Up-Regulation | 2 | 2004 | 848 | 0.050 |
Why?
| | G2 Phase | 1 | 2002 | 39 | 0.050 |
Why?
| | G1 Phase | 1 | 2002 | 65 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 375 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 64 | 0.050 |
Why?
| | Viral Proteins | 1 | 2005 | 350 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2011 | 3416 | 0.050 |
Why?
| | Radioimmunoassay | 2 | 1992 | 165 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2003 | 538 | 0.050 |
Why?
| | Peptide Elongation Factors | 1 | 2022 | 15 | 0.050 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 85 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2005 | 474 | 0.040 |
Why?
| | Transcription Factors | 1 | 2010 | 1736 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2002 | 234 | 0.040 |
Why?
| | Haplotypes | 1 | 2003 | 500 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2003 | 1049 | 0.040 |
Why?
| | Vitamin D3 24-Hydroxylase | 2 | 2015 | 17 | 0.040 |
Why?
| | Kinetics | 2 | 1996 | 1568 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 308 | 0.040 |
Why?
| | Founder Effect | 1 | 2000 | 13 | 0.040 |
Why?
| | Multienzyme Complexes | 1 | 2000 | 65 | 0.040 |
Why?
| | Codon, Nonsense | 1 | 2000 | 45 | 0.040 |
Why?
| | Glyceric Acids | 1 | 2000 | 4 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2000 | 36 | 0.040 |
Why?
| | Mixed Function Oxygenases | 1 | 2000 | 43 | 0.040 |
Why?
| | Aged | 6 | 2013 | 26215 | 0.040 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1999 | 26 | 0.040 |
Why?
| | Consensus Sequence | 1 | 1999 | 73 | 0.040 |
Why?
| | Gene Knockdown Techniques | 2 | 2011 | 334 | 0.040 |
Why?
| | Chemoprevention | 1 | 2000 | 92 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2000 | 157 | 0.040 |
Why?
| | Trans-Activators | 1 | 2022 | 396 | 0.040 |
Why?
| | COS Cells | 1 | 1999 | 177 | 0.040 |
Why?
| | Codon | 1 | 1999 | 92 | 0.040 |
Why?
| | Genes | 1 | 1999 | 228 | 0.040 |
Why?
| | Parenchymal Tissue | 1 | 2019 | 4 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2000 | 335 | 0.040 |
Why?
| | Green Fluorescent Proteins | 2 | 2015 | 407 | 0.040 |
Why?
| | Cell Death | 2 | 2015 | 382 | 0.040 |
Why?
| | Transcriptional Regulator ERG | 1 | 2019 | 14 | 0.040 |
Why?
| | Time Factors | 4 | 2009 | 7133 | 0.040 |
Why?
| | Sequence Alignment | 1 | 1999 | 362 | 0.040 |
Why?
| | Transaminases | 2 | 2011 | 22 | 0.040 |
Why?
| | Sweden | 2 | 2009 | 115 | 0.040 |
Why?
| | Phenotype | 1 | 2007 | 3170 | 0.040 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 26 | 0.030 |
Why?
| | Species Specificity | 1 | 1999 | 546 | 0.030 |
Why?
| | Exons | 1 | 1999 | 364 | 0.030 |
Why?
| | Serine Endopeptidases | 1 | 2019 | 129 | 0.030 |
Why?
| | Acrylamides | 1 | 2018 | 74 | 0.030 |
Why?
| | Cellular Reprogramming | 1 | 2018 | 98 | 0.030 |
Why?
| | Tretinoin | 1 | 2018 | 125 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1368 | 0.030 |
Why?
| | Piperidines | 1 | 2018 | 222 | 0.030 |
Why?
| | Receptors, Death Domain | 1 | 2016 | 4 | 0.030 |
Why?
| | Autophagy-Related Protein 5 | 1 | 2016 | 8 | 0.030 |
Why?
| | Autophagosomes | 1 | 2016 | 20 | 0.030 |
Why?
| | Protein Kinases | 1 | 2018 | 312 | 0.030 |
Why?
| | Biomarkers | 1 | 2007 | 4302 | 0.030 |
Why?
| | Mitochondria | 2 | 2018 | 992 | 0.030 |
Why?
| | Prevalence | 1 | 2003 | 2874 | 0.030 |
Why?
| | Culture Media | 1 | 1996 | 161 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 1996 | 162 | 0.030 |
Why?
| | Cell Survival | 2 | 2011 | 1103 | 0.030 |
Why?
| | Epithelium | 1 | 1996 | 311 | 0.030 |
Why?
| | Genes, Viral | 1 | 2015 | 88 | 0.030 |
Why?
| | Fatty Acids | 1 | 2018 | 457 | 0.030 |
Why?
| | Pregnancy | 3 | 1992 | 7215 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 143 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2015 | 66 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2005 | 88 | 0.030 |
Why?
| | Pertussis Toxin | 2 | 2005 | 24 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2005 | 4568 | 0.030 |
Why?
| | Caspases | 2 | 2005 | 233 | 0.030 |
Why?
| | Case-Control Studies | 3 | 2009 | 3634 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 343 | 0.020 |
Why?
| | Lipids | 1 | 2018 | 707 | 0.020 |
Why?
| | Placental Lactogen | 1 | 1992 | 17 | 0.020 |
Why?
| | Female | 5 | 2006 | 79035 | 0.020 |
Why?
| | Sheep | 1 | 2015 | 876 | 0.020 |
Why?
| | Phosphorylation | 2 | 2010 | 1708 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1992 | 203 | 0.020 |
Why?
| | Models, Biological | 1 | 2000 | 1764 | 0.020 |
Why?
| | Microsomes, Liver | 1 | 1992 | 85 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1996 | 1723 | 0.020 |
Why?
| | Nephrocalcinosis | 1 | 2011 | 12 | 0.020 |
Why?
| | Protein Binding | 2 | 2010 | 2240 | 0.020 |
Why?
| | Animal Feed | 1 | 2011 | 49 | 0.020 |
Why?
| | Binding, Competitive | 1 | 1992 | 185 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 1042 | 0.020 |
Why?
| | Orchiectomy | 1 | 2011 | 72 | 0.020 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2011 | 47 | 0.020 |
Why?
| | Fatty Acid Desaturases | 1 | 2011 | 31 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2011 | 170 | 0.020 |
Why?
| | Gene Knockout Techniques | 1 | 2011 | 119 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 199 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2011 | 246 | 0.020 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 2000 | 0.020 |
Why?
| | Proteolysis | 1 | 2011 | 172 | 0.020 |
Why?
| | Spheroids, Cellular | 1 | 2011 | 74 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1995 | 696 | 0.020 |
Why?
| | Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2010 | 1 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 155 | 0.020 |
Why?
| | Rabbits | 1 | 1992 | 653 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2069 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1083 | 0.020 |
Why?
| | S Phase | 1 | 2010 | 78 | 0.020 |
Why?
| | Antioxidants | 1 | 2014 | 550 | 0.020 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2010 | 55 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 287 | 0.020 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2015 | 420 | 0.020 |
Why?
| | Ubiquitination | 1 | 2010 | 119 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 331 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2525 | 0.020 |
Why?
| | Pulmonary Artery | 1 | 2015 | 1129 | 0.020 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2010 | 79 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2011 | 741 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1474 | 0.020 |
Why?
| | HeLa Cells | 1 | 2010 | 632 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 762 | 0.020 |
Why?
| | Computer Simulation | 1 | 2011 | 1003 | 0.020 |
Why?
| | Antigens, CD | 1 | 2010 | 558 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2011 | 2191 | 0.010 |
Why?
| | Placenta | 1 | 1992 | 787 | 0.010 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2005 | 17 | 0.010 |
Why?
| | Prostaglandin D2 | 1 | 2005 | 21 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1547 | 0.010 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2005 | 9 | 0.010 |
Why?
| | Anilides | 1 | 2005 | 84 | 0.010 |
Why?
| | ADP-Ribosylation Factors | 1 | 2005 | 18 | 0.010 |
Why?
| | Caspase 8 | 1 | 2005 | 48 | 0.010 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2005 | 53 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2004 | 40 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2005 | 61 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2005 | 72 | 0.010 |
Why?
| | Peroxisomes | 1 | 2004 | 11 | 0.010 |
Why?
| | Caspase 3 | 1 | 2005 | 242 | 0.010 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2004 | 112 | 0.010 |
Why?
| | PPAR gamma | 1 | 2005 | 182 | 0.010 |
Why?
| | Mitosis | 1 | 2005 | 193 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2005 | 414 | 0.010 |
Why?
| | Prognosis | 1 | 2013 | 4329 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2005 | 187 | 0.010 |
Why?
| | Adenoviridae | 1 | 2005 | 199 | 0.010 |
Why?
| | Diet | 1 | 2011 | 1278 | 0.010 |
Why?
| | Models, Molecular | 1 | 2009 | 1599 | 0.010 |
Why?
| | Radiation, Ionizing | 1 | 2003 | 86 | 0.010 |
Why?
| | Phagocytosis | 1 | 2005 | 296 | 0.010 |
Why?
| | Chlorobenzenes | 1 | 2002 | 18 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 2002 | 52 | 0.010 |
Why?
| | Carcinoma | 1 | 2005 | 227 | 0.010 |
Why?
| | DNA Primers | 1 | 2004 | 505 | 0.010 |
Why?
| | Benzoquinones | 1 | 2002 | 46 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 855 | 0.010 |
Why?
| | Cattle | 1 | 2005 | 946 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 136 | 0.010 |
Why?
| | Binding Sites | 1 | 2005 | 1311 | 0.010 |
Why?
| | GTP-Binding Proteins | 1 | 2002 | 153 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 172 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1261 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 426 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 457 | 0.010 |
Why?
| | Virus Replication | 1 | 2004 | 521 | 0.010 |
Why?
| | Probability | 1 | 2002 | 308 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2002 | 288 | 0.010 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2005 | 534 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 17325 | 0.010 |
Why?
| | Inflammation | 1 | 2011 | 2883 | 0.010 |
Why?
| | Registries | 1 | 2009 | 2410 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 1217 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 625 | 0.010 |
Why?
| | Genetic Variation | 1 | 2004 | 976 | 0.010 |
Why?
| | Indoles | 1 | 2002 | 507 | 0.010 |
Why?
| | Cell Count | 1 | 1997 | 319 | 0.010 |
Why?
| | Phorbol Esters | 1 | 1995 | 13 | 0.010 |
Why?
| | Teriparatide | 1 | 1995 | 10 | 0.010 |
Why?
| | Colforsin | 1 | 1995 | 47 | 0.010 |
Why?
| | Second Messenger Systems | 1 | 1995 | 31 | 0.010 |
Why?
| | Osteosarcoma | 1 | 1995 | 89 | 0.010 |
Why?
| | Brain | 1 | 2004 | 2969 | 0.010 |
Why?
| | Cohort Studies | 1 | 2002 | 6032 | 0.010 |
Why?
| | Prospective Studies | 1 | 2002 | 8075 | 0.000 |
Why?
| | Aged, 80 and over | 1 | 2002 | 8346 | 0.000 |
Why?
|
|
Cramer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|